Pfizer eyes takeover of biotech Seagen, at value of more than $30 billion

Pfizer Inc. is in talks to acquire biotech Seagen Inc., according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies.